Q32 Bio Inc
QTTB3.160USD
-0.040-1.25%
Market hours （ET）Quotes delayed by 15 min
38.88MMarket Cap
LossP/E TTM
More Details of Q32 Bio Inc Company
Q32 Bio Inc. is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases. It focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). It has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.
Q32 Bio Inc Info
Ticker SymbolQTTB
Company nameQ32 Bio Inc
IPO dateMar 28, 2018
CEOMorrison (Jodie Pope)
Number of employees42
Security typeOrdinary Share
Fiscal year-endMar 28
Address830 Winter Street
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02451
Phone17819990232
Websitehttps://www.q32bio.com/
Ticker SymbolQTTB
IPO dateMar 28, 2018
CEOMorrison (Jodie Pope)
Company Executives of Q32 Bio Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
57.16K
-4.97%
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
5.43K
--
Dr. David S. Grayzel, M.D.
Dr. David S. Grayzel, M.D.
Independent Director
Independent Director
--
--
Dr. Bill Lundberg, M.D.
Dr. Bill Lundberg, M.D.
Independent Director
Independent Director
--
--
Ms. Jodie Pope Morrison
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Mr. Lee H. Kalowski
Mr. Lee H. Kalowski
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Diyong Xu
Mr. Diyong Xu
Independent Director
Independent Director
--
--
Dr. Isaac Manke
Dr. Isaac Manke
Independent Director
Independent Director
--
--
Ms. Mary T. Thistle, CPA
Ms. Mary T. Thistle, CPA
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
57.16K
-4.97%
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
5.43K
--
Dr. David S. Grayzel, M.D.
Dr. David S. Grayzel, M.D.
Independent Director
Independent Director
--
--
Dr. Bill Lundberg, M.D.
Dr. Bill Lundberg, M.D.
Independent Director
Independent Director
--
--
Ms. Jodie Pope Morrison
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Mr. Lee H. Kalowski
Mr. Lee H. Kalowski
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Revenue Breakdown
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
OrbiMed Advisors, LLC
18.31%
Atlas Venture
17.00%
Abingworth Management Limited
8.96%
Acorn Capital Advisors, LLC
6.53%
ARCH Venture Partners
2.60%
Other
46.59%
Shareholders
Shareholders
Proportion
OrbiMed Advisors, LLC
18.31%
Atlas Venture
17.00%
Abingworth Management Limited
8.96%
Acorn Capital Advisors, LLC
6.53%
ARCH Venture Partners
2.60%
Other
46.59%
Shareholder Types
Shareholders
Proportion
Venture Capital
28.57%
Private Equity
18.31%
Investment Advisor
13.97%
Corporation
5.87%
Hedge Fund
1.96%
Investment Advisor/Hedge Fund
1.50%
Individual Investor
0.62%
Research Firm
0.11%
Other
29.10%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
197
8.50M
69.71%
-4.30M
2025Q2
211
9.72M
79.73%
-4.89M
2025Q1
223
10.26M
84.16%
-4.38M
2024Q4
223
11.35M
93.20%
-1.04M
2024Q3
208
11.60M
102.62%
+2.77M
2024Q2
197
10.02M
90.20%
+1.83M
2024Q1
230
9.37M
85.14%
+7.24M
2023Q4
242
1.68M
52.16%
-377.72K
2023Q3
262
1.62M
50.50%
-460.61K
2023Q2
275
1.63M
50.84%
-543.11K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
OrbiMed Advisors, LLC
2.25M
18.47%
--
--
Jun 30, 2025
Atlas Venture
2.09M
17.15%
--
--
Jun 30, 2025
Abingworth Management Limited
1.10M
9.04%
--
--
Jun 30, 2025
Acorn Capital Advisors, LLC
803.42K
6.59%
--
--
Jun 30, 2025
ARCH Venture Partners
320.48K
2.63%
--
--
Jun 30, 2025
Monaco asset management S.A.M.
591.94K
4.85%
+86.49K
+17.11%
Jun 30, 2025
The Vanguard Group, Inc.
269.43K
2.21%
-39.78K
-12.87%
Jun 30, 2025
Pfizer Inc
277.78K
2.28%
--
--
Jun 30, 2025
Sanofi SA
244.08K
2%
--
--
Jun 30, 2025
Bristol Myers Squibb
200.24K
1.64%
-558.90K
-73.62%
Dec 31, 2024
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 ETF
0%
Hypatia Women CEO ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares UltraPro Russell2000
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Goldman Sachs Innovate Equity ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Value ETF
0%
Avantis US Small Cap Equity ETF
0%
View more
Fidelity Enhanced Small Cap ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Hypatia Women CEO ETF
Proportion0%
Invesco Nasdaq Biotechnology ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Goldman Sachs Innovate Equity ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
Date
Type
Ratio
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
FAQs
Who are the top five shareholders of Q32 Bio Inc?
The top five shareholders of Q32 Bio Inc are:
OrbiMed Advisors, LLC holds 2.25M shares, accounting for 18.47% of the total shares.
Atlas Venture holds 2.09M shares, accounting for 17.15% of the total shares.
Abingworth Management Limited holds 1.10M shares, accounting for 9.04% of the total shares.
Acorn Capital Advisors, LLC holds 803.42K shares, accounting for 6.59% of the total shares.
ARCH Venture Partners holds 320.48K shares, accounting for 2.63% of the total shares.
OrbiMed Advisors, LLC holds 2.25M shares, accounting for 18.47% of the total shares.
Atlas Venture holds 2.09M shares, accounting for 17.15% of the total shares.
Abingworth Management Limited holds 1.10M shares, accounting for 9.04% of the total shares.
Acorn Capital Advisors, LLC holds 803.42K shares, accounting for 6.59% of the total shares.
ARCH Venture Partners holds 320.48K shares, accounting for 2.63% of the total shares.
What are the top three shareholder types of Q32 Bio Inc?
The top three shareholder types of Q32 Bio Inc are:
OrbiMed Advisors, LLC
Atlas Venture
Abingworth Management Limited
OrbiMed Advisors, LLC
Atlas Venture
Abingworth Management Limited
How many institutions hold shares of Q32 Bio Inc (QTTB)?
As of 2025Q3, 197 institutions hold shares of Q32 Bio Inc, with a combined market value of approximately 8.50M, accounting for 69.71% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -10.02%.
What is the biggest source of revenue for Q32 Bio Inc?
In FY2024, the -- business generated the highest revenue for Q32 Bio Inc, amounting to -- and accounting for --% of total revenue.
